Inclusion Criteria:

- Prior or current diagnosis Durie-Salmon stage II or III multiple myeloma.

- Measurable levels of myeloma paraprotein in serum or urine (24-hour collection
sample).

- Eastern Cooperative Oncology Group (ECOG) performance status score of 0,1, or 2

- Females of childbearing potential must have a negative serum or urine pregnancy test
within 7 days of starting study drug

Exclusion Criteria:

- Prior development of disease progression during high-dose dexamethasone containing
therapy

- Pregnant or lactating females

- The development of a desquamating rash while taking thalidomide

- Use of any standard/experimental anti-myeloma therapy within 28 days of randomization
or use of any experimental non-drug therapy within 56 days of initiation of drug
treatment

- Laboratory abnormalities: Absolute neutrophil count less than 1,000 cells/mm3

- Laboratory abnormalities: Platelet count < 75,000/mm3

- Laboratory abnormalities: Serum creatinine > 2.5 mg/dL

- Laboratory abnormalities: Serum Serum glutamic oxaloacetic transaminase
(SGOT)/Aspartate aminotransferase (AST) or Serum glutamic pyruvic transaminase
(SGPT)/Alanine aminotransferase (ALT) > 3.0 x upper limit of normal

- Laboratory abnormalities: Serum total bilirubin > 2.0 mg/dL

- Prior history of malignancies other than multiple myeloma unless the subject has been
free of the disease for ≥ 3 years.